These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

705 related items for PubMed ID: 15569371

  • 21. Evaluation of p53 protein expression in Barrett's esophagus by two-parameter flow cytometry.
    Ramel S, Reid BJ, Sanchez CA, Blount PL, Levine DS, Neshat K, Haggitt RC, Dean PJ, Thor K, Rabinovitch PS.
    Gastroenterology; 1992 Apr; 102(4 Pt 1):1220-8. PubMed ID: 1551529
    [Abstract] [Full Text] [Related]

  • 22. Detection of the risk of adenocarcinoma in Barrett's esophagus by means of tumor markers (p53 and Ki67).
    Trakál E, Guidi A, Butti AL, Trakál JJ, Sambuelli R, Zárate FE.
    Acta Gastroenterol Latinoam; 2010 Sep; 40(3):211-5. PubMed ID: 21049770
    [Abstract] [Full Text] [Related]

  • 23. High-grade dysplasia and superficial adenocarcinoma in Barrett's esophagus: histological mapping and expression of p53, p21 and Bcl-2 oncoproteins.
    Chatelain D, Fléjou JF.
    Virchows Arch; 2003 Jan; 442(1):18-24. PubMed ID: 12536310
    [Abstract] [Full Text] [Related]

  • 24. Transforming growth factor-alpha, epidermal growth factor receptor, and MiB-1 expression in Barrett's-associated neoplasia: correlation with prognosis.
    Yacoub L, Goldman H, Odze RD.
    Mod Pathol; 1997 Feb; 10(2):105-12. PubMed ID: 9127315
    [Abstract] [Full Text] [Related]

  • 25. [Histochemical diagnosis of short segment Barrett's esophagus].
    Fujiyama Y, Ishizuka I, Koyama S.
    Nihon Rinsho; 2005 Aug; 63(8):1420-6. PubMed ID: 16101233
    [Abstract] [Full Text] [Related]

  • 26. Increased CDX2 and decreased PITX1 homeobox gene expression in Barrett's esophagus and Barrett's-associated adenocarcinoma.
    Lord RV, Brabender J, Wickramasinghe K, DeMeester SR, Holscher A, Schneider PM, Danenberg PV, DeMeester TR.
    Surgery; 2005 Nov; 138(5):924-31. PubMed ID: 16291394
    [Abstract] [Full Text] [Related]

  • 27. Prospective study of cyclin D1 overexpression in Barrett's esophagus: association with increased risk of adenocarcinoma.
    Bani-Hani K, Martin IG, Hardie LJ, Mapstone N, Briggs JA, Forman D, Wild CP.
    J Natl Cancer Inst; 2000 Aug 16; 92(16):1316-21. PubMed ID: 10944553
    [Abstract] [Full Text] [Related]

  • 28. The value of p53 and Ki67 as markers for tumour progression in the Barrett's dysplasia-carcinoma sequence.
    Polkowski W, van Lanschot JJ, Ten Kate FJ, Baak JP, Tytgat GN, Obertop H, Voorn WJ, Offerhaus GJ.
    Surg Oncol; 1995 Jun 16; 4(3):163-71. PubMed ID: 7582189
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Analysis of Ki-67, p53 and Bcl-2 expression in the dysplasia-carcinoma sequence of Barrett's esophagus.
    Rioux-Leclercq N, Turlin B, Sutherland F, Heresbach N, Launois B, Campion JP, Ramee MP.
    Oncol Rep; 1999 Jun 16; 6(4):877-82. PubMed ID: 10373674
    [Abstract] [Full Text] [Related]

  • 34. Progression of Barrett's metaplasia to adenocarcinoma is associated with the suppression of the transcriptional programs of epidermal differentiation.
    Kimchi ET, Posner MC, Park JO, Darga TE, Kocherginsky M, Karrison T, Hart J, Smith KD, Mezhir JJ, Weichselbaum RR, Khodarev NN.
    Cancer Res; 2005 Apr 15; 65(8):3146-54. PubMed ID: 15833844
    [Abstract] [Full Text] [Related]

  • 35. Mucin expression and proliferating cell index of esophageal Barrett's adenocarcinoma.
    Yamamoto S, Kijima H, Hara T, Chino O, Shimada H, Tanaka M, Inokuchi S, Makuuchi H.
    Int J Mol Med; 2005 Sep 15; 16(3):375-80. PubMed ID: 16077942
    [Abstract] [Full Text] [Related]

  • 36. Histopathologic evaluation of an animal model for Barrett's esophagus and adenocarcinoma of the distal esophagus.
    Buskens CJ, Hulscher JB, van Gulik TM, Ten Kate FJ, van Lanschot JJ.
    J Surg Res; 2006 Oct 15; 135(2):337-44. PubMed ID: 16926029
    [Abstract] [Full Text] [Related]

  • 37. Barrett's esophagus: metaplastic cells with loss of heterozygosity at the APC gene locus are clonal precursors to invasive adenocarcinoma.
    Zhuang Z, Vortmeyer AO, Mark EJ, Odze R, Emmert-Buck MR, Merino MJ, Moon H, Liotta LA, Duray PH.
    Cancer Res; 1996 May 01; 56(9):1961-4. PubMed ID: 8616831
    [Abstract] [Full Text] [Related]

  • 38. P53 mutational status improves estimation of prognosis in patients with curatively resected adenocarcinoma in Barrett's esophagus.
    Schneider PM, Stoeltzing O, Roth JA, Hoelscher AH, Wegerer S, Mizumoto S, Becker K, Dittler HJ, Fink U, Siewert JR.
    Clin Cancer Res; 2000 Aug 01; 6(8):3153-8. PubMed ID: 10955797
    [Abstract] [Full Text] [Related]

  • 39. Cdx2 expression and its promoter methylation during metaplasia-dysplasia-carcinoma sequence in Barrett's esophagus.
    Makita K, Kitazawa R, Semba S, Fujiishi K, Nakagawa M, Haraguchi R, Kitazawa S.
    World J Gastroenterol; 2013 Jan 28; 19(4):536-41. PubMed ID: 23382633
    [Abstract] [Full Text] [Related]

  • 40. Malignant progression in Barrett's esophagus: pathology and molecular biology.
    Mueller J, Werner M, Siewert JR.
    Recent Results Cancer Res; 2000 Jan 28; 155():29-41. PubMed ID: 10693236
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 36.